The patient being treated at Emory, who was admitted in early September and about whom few details are known, released a statement Wednesday.
"Given the national focus on Ebola, particularly with the diagnosis in two health-care workers, I want to share the news that I am recovering from this disease, and that I anticipate being discharged very soon, free from the Ebola virus and able to return safely to my family and to my community," the anonymous patient said. "As a result of the virus, my condition worsened and I became critically ill soon after I arrived at Emory. Through rigorous medical treatment, skillful nursing and the full support of a health-care team, I am well on the way to a full recovery."
Read MoreUN: Ebola fund only has $100,000 in bank
Vinson, who was diagnosed Wednesday, was transferred from Dallas to Emory later the same day for treatment. If she's receiving an experimental drug, the treatment decision was made swiftly. Pham, who was diagnosed Sunday, was moved Thursday to a treatment center at the National Institutes of Health.
Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said the NIH can't discuss Pham's treatment because of privacy concerns, though he noted she did receive a transfusion of plasma from Brantly.
"At this point in time, we are still working with the patient about what we can say publicly," Fauci said in a news conference Friday. "In terms of other, quote, experimental drugs, we will have to check with her whether she wants this to be known publicly because of patient confidentiality."
Fauci said that in general, it would be possible for patients to receive more than one experimental therapy, "but we've got to be careful, because these are all experimental drugs," and none have been proven to be effective. Safety is also a key concern in considering combining therapies, he said.
CDC's Frieden has said treatment decisions, including experimental drugs, are up to the patients, their families and their physicians.
Similarly to the first group of patients, few conclusions can be drawn from knowing these patients may be receiving experimental therapy. Of course, that doesn't stop the market from reacting to news.
(UPDATE: This story was updated to include comments from Dr. Anthony Fauci.)